Yamada, Yasuhide
Nagashima, Kengo
Azuma, Mizutomo
Masutani, Mitsuko
Ichikawa, Hitoshi
Iwasa, Satoru
Takahashi, Naoki
Hirano, Hidekazu
Kanato, Keisuke
Machida, Nozomu
Kinoshita, Takahiro
Hata, Hiroaki
Kawakami, Hisato
Takahari, Daisuke
Boku, Narikazu
Kurokawa, Yukinori
Terashima, Masanori
Yoshikawa, Takaki
Sekine, Shigeki
Hiraoka, Nobuyoshi
Funding for this research was provided by:
National Center for Global Health and Medicine (NCGM Intramural Reasearch Fund, 20A1014, NCGM Intramural Reasearch Fund, 20A1014, NCGM Intramural Reasearch Fund, 20A1014, NCGM Intramural Reasearch Fund, 20A1014, NCGM Intramural Reasearch Fund, 20A1014, NCGM Intramural Reasearch Fund, 20A1014, NCGM Intramural Reasearch Fund, 20A1014, NCGM Intramural Reasearch Fund, 20A1014)
National Cancer Center Japan (National Cancer Research and Development Fund, 2020-J-3, 2023-J-03)
Article History
Received: 21 November 2023
Revised: 29 January 2024
Accepted: 31 January 2024
First Online: 5 March 2024
Competing interests
: Y. Yamada has received lecture fee from Taiho Pharmaceutical. K. Nagashima has received consulting fee from Senju Pharmaceutical, Toray Industries, and Kowa. S. Iwasa is the employee of Chugai Pharma, and has received honoraria from Taiho Pharmaceutical, Lilly Japan, Chugai Pharma, Ono Pharmaceutical, Daiichi-Sankyo, Bristol-Myers Squibb Japan, and Agilent, institutional research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Eisai, Merck Serono, Bayer, Ono Pharmaceutical, Astellas Pharma, Pfizer, Seagen, Zymeworks, Taiho Pharmaceutical, and AstraZeneca. N. Takahashi has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb Japan, and Taiho Pharmaceutical. H. Hirano has received honoraria Bristol-Myers Squibb Japan, Chugai Pharma, Novartis, Taiho Pharmaceutical, Fujifilm, and Teijin Pharma, and institutional research funding BeiGene. N. Machida has received honoraria from Taiho Pharmaceutical, Bristol-Myers Squibb Japan, Ono Pharmaceutical, Daiichi-Sankyo, Lilly Japan, Yakult Honsha, Takeda, MSD K.K, Chugai Pharma, Merck KGaA, Novartis, and Astellas Pharma, and institutional research funding from MSD, AstraZeneca, Amgen, Ono Pharmaceutical, Taiho Pharmaceutical, ALX Oncology, and Bristol-Myers Squibb Japan. T. Kinoshita has received lecture fees from Johnson & Johnson, Intuitive Surgical, Medtronic, Olympus Medical Systems, Daiichi Sankyo, Lilly Japan, Bristol-Myers Squibb Japan, Kaken Pharmaceutical, and Taiho Pharmaceutical. H. Kawakami has received cousulting fee from Taiho Pharmaceutical, Bristol-Myers Squibb Japan, Ono Pharmaceutical, Lilly Japan, and Daiichi-Sankyo, honoraria from Chugai Pharma/ Roche, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Yakult Honsha, Takeda, MSD K.K, Merck Serono, Lilly Japan, Daiichi-Sankyo, Bayer, and institutional research funding from Chugai Pharma, Daiichi-Sankyo, Eisai, Kobayashi Pharmaceutical. D. Takahari has received honoraria, Taiho Pharmaceutical, Lilly Japan, Ono Pharmaceutical, Yakult Honsha, Bristol-Myers Squibb Japan, and Daiichi-Sankyo/UCB Japan, and institutional research funding from Ono Pharmaceutical and Taiho Pharmaceutical. N. Boku has received honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Daiichi-Sankyo, Lilly, and institutional research funding from Ono Pharmaceutical and Takeda. Y. Kurokawa has received lecture fees from Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, Lilly, Nippon Kayaku, and Kaken Pharmaceutical, and research fundings from Taiho Pharmaceutical, Yakult Honsha, AstraZeneca, Ono Pharmaceutical, and MSD Oncology outside of the submitted work. M. Terashima has received honoraria from Chugai Pharma, Taiho Pharmaceutical, Lilly, Ono Pharmaceutical, Bristol-Myers Squibb, Daiichi-Sankyo, Yakult Honsha, Johnson & Johnson, Olympus, and Intuitive Surgical. T. Yoshikawa has received consulting fee from MSD Oncology and TERUMO, honoraria from Chugai Pharma, Taiho Pharmaceutical, Daiichi-Sankyo, Ono Pharmaceutical, Medtronic, Bristol-Myers Squibb, EA Pharma, Johnson & Johnson/ Janssen, AstraZeneca, Intuitive Surgical, Japan Blood Products Organization, Olympus, Lilly, Astellas Pharma, and research funding from Lilly. S. Sekine has received honoraria from MSD and Roche, and institutional research funding from AstraZeneca. M. Azuma, M. Masutani, H. Ichikawa, K. Kanato, and H. Hata, and N. Hiraoka have no relationships to disclose.
: Written informed consent to be enrolled in JCOG1013 was obtained before registration and the opportunity to refuse to provide tumor samples was provided through web sites of the National Cancer Center and the Japan Clinical Oncology Group (JCOG) according to the Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects. The protocol of this translational study was approved by the institutional review board of the National Center for Global Health and Medicine and each participating hospital and complied according to the criteria of REMARK (reporting recommendations for tumor marker prognostic studies.